CETP Inhibitor Obicetrapib Moves Forward in EMA Review, With Dual Cardiovascular and Neurology Impact
Written by
Neurology Live
Published
0
comments
0
min
The European Medicines Agency has accepted NewAmsterdam Pharma’s application for obicetrapib, an oral CETP inhibitor that lowers LDL-C and shows promise in reducing Alzheimer-related biomarkers.